IMF Videos Search Content For Care Partner (51) Patient (49) Healthcare Professional (37) Healthcare Provider (37) Series - Any - ASCO/EHA (16) ASH (10) Ask Dr. Durie (19) Black Swan Research Initiative (3) Community Workshops (3) Emerging Therapies (4) Facebook Live (2) Health Equity (3) IMWG (1) Living Well with Myeloma (3) Myeloma in a Minute (4) Myeloma Made Simple (3) Myeloma University (4) Patient & Family Webinar (1) Q&A (3) Recent News and Developments (1) Topics Clinical Trials (184) Financial Considerations (15) Frontline Therapy (81) Health Equity (33) Inspirational Stories (23) Insurance (6) Lab & Imaging Tests (68) Lifestyle (47) Mental & Emotional Health (28) Myeloma 101 (54) Myeloma in the News (7) Public Policy & Advocacy (17) Q&A's (41) Recorded Seminars & Workshops (14) Recorded Webinars (23) Relapse/Refractory Myeloma (135) Research Updates (192) Symptom Management (113) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (19) High-Risk Myeloma (24) High-risk Smoldering Myeloma (12) Late Relapse (4–6 Lines of Therapy) (15) MGUS (14) Newly Diagnosed (Pre-Treatment or First Treatment) (69) Smoldering Myeloma (23) Types of Therapy Immunomodulatory drugs (IMiDs) (37) Immunotherapies (CAR T; BiTE, etc.) (22) Monoclonal antibodies (27) Proteasome inhibitors (31) Stem cell transplant (38) Steroids (28) Supportive Care (17) Year Published 2026 (6) 2025 (16) 2024 (19) 2023 (13) 2022 (3) 2021 (4) 2019 (5) 2018 (2) 2017 (4) 2016 (5) 2015 (4) Trusted Voices Dr. Brian GM Durie (20) Dr. Joseph Mikhael (20) Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (6) Dr. Shaji Kumar (2) Donna Catamero, ANP-BC, OCN, CCRC (1) Dr. María-Victoria Mateos (1) Dr. Saad Usmani (1) Dr. Sigurður Kristinsson (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Quadruplet Induction Therapy, ASCT and MRD-modulated Consolidation and Treatment Cessation in Newly Diagnosed Multiple Myeloma July 1, 2023 ASCO/EHA Maintenance Therapy with Carfilzomib, Pomalidomide, and Dex (KPd) in High-Risk Myeloma Patients June 30, 2023 ASCO/EHA DREAMM-9: Belantamab mafodotin + Standard Care in Newly Diagnosed Multiple Myeloma June 22, 2023 ASCO/EHA Living Well with Myeloma Webinar - New Drugs in Myeloma – What, How and When? What Patients and Care Partners Need to Know March 30, 2023 Living Well with Myeloma Fixed Duration Therapy with Dara-KRd for High Risk Smoldering Multiple Myeloma: ASCENT Trial February 3, 2023 ASH Multiple Myeloma Transplant: Examining the Intersection of Access, Age and Race January 27, 2023 ASH Curative Strategy (GEM-CESAR) for High-Risk Smoldering Myeloma: Post-Hoc Analysis of Sustained Undetectable MRD December 22, 2022 ASH MRD2STOP: Can multimodal MRD negativity guide discontinuation of maintenance treatment in myeloma? December 13, 2022 ASH Should patients see a multiple myeloma expert? September 22, 2022 Ask Dr. Durie M-Power Atlanta Community Workshop November 16, 2021 Health Equity M-Power Baltimore Community Workshop September 21, 2021 Health Equity Can myeloma maintenance therapy be adjusted? August 11, 2021 Ask Dr. Durie Load More
